372 related articles for article (PubMed ID: 27020587)
1. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
2. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
[TBL] [Abstract][Full Text] [Related]
3. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
[TBL] [Abstract][Full Text] [Related]
4. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
[TBL] [Abstract][Full Text] [Related]
5. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.
Zhou P; Goffredo P; Ginader T; Thompson D; Hrabe J; Gribovskaja-Rupp I; Kapadia M; Hassan I
J Surg Oncol; 2021 Jan; 123(1):278-285. PubMed ID: 33022750
[TBL] [Abstract][Full Text] [Related]
6. Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
Gollins S; West N; Sebag-Montefiore D; Myint AS; Saunders M; Susnerwala S; Quirke P; Essapen S; Samuel L; Sizer B; Worlding J; Southward K; Hemmings G; Tinkler-Hundal E; Taylor M; Bottomley D; Chambers P; Lawrie E; Lopes A; Beare S
Br J Cancer; 2017 Oct; 117(9):1286-1294. PubMed ID: 28859058
[TBL] [Abstract][Full Text] [Related]
7. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
[TBL] [Abstract][Full Text] [Related]
9. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N
Ann Oncol; 2015 Sep; 26(9):1936-1941. PubMed ID: 26162609
[TBL] [Abstract][Full Text] [Related]
11. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
[TBL] [Abstract][Full Text] [Related]
12. Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics.
Krajnović M; Marković B; Knežević-Ušaj S; Nikolić I; Stanojević M; Nikolić V; Šiljić M; Jovanović Ćupić S; Dimitrijević B
Pathol Res Pract; 2016 Jul; 212(7):598-603. PubMed ID: 27184911
[TBL] [Abstract][Full Text] [Related]
13. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
14.
Sideris M; Moorhead J; Diaz-Cano S; Haji A; Papagrigoriadis S
Anticancer Res; 2017 Mar; 37(3):1349-1357. PubMed ID: 28314302
[TBL] [Abstract][Full Text] [Related]
15. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy.
Hall MD; Schultheiss TE; Smith DD; Fakih MG; Wong JY; Chen YJ
Acta Oncol; 2016 Dec; 55(12):1392-1399. PubMed ID: 27762654
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.
Clancy C; Burke JP; Coffey JC
Surg Oncol; 2013 Jun; 22(2):105-11. PubMed ID: 23473635
[TBL] [Abstract][Full Text] [Related]
17. Molecular Predictors of Response to Neoadjuvant Chemoradiation for Rectal Cancer.
Kundel Y; Nasser NJ; Rath-Wolfson L; Purim O; Yanichkin N; Brenner R; Zehavi T; Nardi Y; Fenig E; Sulkes A; Brenner B
Am J Clin Oncol; 2018 Jun; 41(6):613-618. PubMed ID: 27740975
[TBL] [Abstract][Full Text] [Related]
18. Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.
Chen Z; Duldulao MP; Li W; Lee W; Kim J; Garcia-Aguilar J
J Am Coll Surg; 2011 Jun; 212(6):1008-1017.e1. PubMed ID: 21458303
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment Tumor Thickness as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy for Stage II/III Rectal Adenocarcinoma.
Xu B; Chen Y; Guo Y; Zhou D; Yue Z; Duan Q; Yang Y; Guan G; Chi P; Lin C
Am J Clin Oncol; 2018 Jun; 41(6):601-606. PubMed ID: 27672742
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.
Grimminger PP; Danenberg P; Dellas K; Arnold D; Rödel C; Machiels JP; Haustermans K; Debucquoy A; Velenik V; Sempoux C; Bracko M; Hölscher AH; Semrau R; Yang D; Danenberg K; Lenz HJ; Vallböhmer D
Clin Cancer Res; 2011 May; 17(10):3469-77. PubMed ID: 21558395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
